Open access
2026
Combined Inhibition of EZH2 and HMGA1 Affects Gastric Carcinoma Cell Viability
: Background: With limited treatment options and suboptimal clinical outcomes, gastric adenocarcinoma (GAC) remains a major global health burden. Enhancer of zeste homolog 2 (EZH2) and high mobility group A1 (HMGA1) are frequently upregulated in several human cancers and are associated with key oncogenic processes, inc...
M. De Martino, V. Franco, Simona Pellecchia et al.
· Oncology Research · 0 citations